Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Seppo Yla-Herttuala"'
Autor:
Alexis R. Steinmetz, Morgan Pierce, Alberto Martini, Come Tholomier, Ganiraju Manyam, Yan Chen, Akshay Sood, Jonathan J. Duplisea, Burles A. Johnson, Bogdan A. Czerniak, Byron H. Lee, Chinnaswamy Jagannath, Seppo Yla-Herttuala, Nigel R. Parker, David J. McConkey, Colin P. Dinney, Sharada Mokkapati
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionNadofaragene firadenovec (Ad-IFNα/Syn3) is now approved for BCG-unresponsive bladder cancer (BLCA). IFNα is a pleiotropic cytokine that causes direct tumor cell killing via TRAIL-mediated apoptosis, angiogenesis inhibition, and activati
Externí odkaz:
https://doaj.org/article/63a622d2fe494a5898ec7dc003c1d01b
Autor:
Sharada Mokkapati, Vikram M. Narayan, Ganiraju C. Manyam, Amy H. Lim, Jonathan J. Duplisea, Andrea Kokorovic, Tanner S. Miest, Anirban P. Mitra, Devin Plote, Selvalakshmi Selvaraj Anand, Michael J. Metcalfe, Kenneth Dunner, Jr., Burles A. Johnson, Bogdan A. Czerniak, Tiina Nieminen, Tommi Heikura, Seppo Yla-Herttuala, Nigel R. Parker, Kimberley S. Schluns, David J. McConkey, Colin P. Dinney
Publikováno v:
Molecular Therapy: Oncolytics, Vol 26, Iss , Pp 141-157 (2022)
Interferon alpha (IFNα) gene therapy is emerging as a new treatment option for patients with non-muscle invasive bladder cancer (NMIBC). Adenoviral vectors expressing IFNα have shown clinical efficacy treating bacillus Calmette-Guerin (BCG)-unrespo
Externí odkaz:
https://doaj.org/article/5de742af926648bcab7840c44c6fac3e
Autor:
Devin Plote, Woonyoung Choi, Sharada Mokkapati, Debasish Sundi, James E Ferguson, Jon Duplisea, Nigel R. Parker, Seppo Yla-Herttuala, SUO CTC Bladder Committee, David McConkey, Kimberly S. Schluns, Colin P. Dinney
Publikováno v:
OncoImmunology, Vol 8, Iss 5 (2019)
Type I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma (UC) and may be an alternative treatment option for patients who do not respond to Bacillus Calmette-Guerin. However, the mechanisms that mediate the IFN-I-stimulate
Externí odkaz:
https://doaj.org/article/8f2fc5baf21f453bade61adaf369e1f7
Autor:
Anirban P. Mitra, Sharada Mokkapati, Tanner S. Miest, Vikram M. Narayan, Richard Philipson, Seppo Yla-Herttuala, David Sawutz, Nigel R. Parker, David J. McConkey, Colin P.N. Dinney
Publikováno v:
Journal of Urology. 207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8eb9fa61aec8b5b7226c3f57a894697d
https://doi.org/10.1097/ju.0000000000002633.05
https://doi.org/10.1097/ju.0000000000002633.05
Autor:
Tiina Nieminen, Tristan A. Scott, Feng-Mao Lin, Zhen Chen, Seppo Yla-Herttuala, Kevin V. Morris
Publikováno v:
Non-Coding RNA, Vol 4, Iss 4, p 34 (2018)
The role and function of long non-coding RNAs (lncRNAs) in modulating gene expression is becoming apparent. Vascular endothelial growth factor A (VEGF-A) is a key regulator of blood vessel formation and maintenance making it a promising therapeutic t
Externí odkaz:
https://doaj.org/article/cb327e31f6f74c74a27ce7c415678504
Autor:
Devin Plote, Woonyoung Choi, Sharada Mokkapati, Debasish Sundi, James E Ferguson, Jon Duplisea, Nigel R. Parker, Seppo Yla-Herttuala, SUO CTC Bladder Committee, David McConkey, Kimberly S. Schluns, Colin P. Dinney
Publikováno v:
Oncoimmunology
OncoImmunology, Vol 8, Iss 5 (2019)
OncoImmunology, Vol 8, Iss 5 (2019)
Type I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma (UC) and may be an alternative treatment option for patients who do not respond to Bacillus Calmette-Guerin. However, the mechanisms that mediate the IFN-I-stimulate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d54d3b2a2c91f74185d01f8fbdf9400
https://pubmed.ncbi.nlm.nih.gov/31069136
https://pubmed.ncbi.nlm.nih.gov/31069136
Publikováno v:
Journal of the American College of Cardiology. 33(2):499-505
ObjectivesThe purpose of this study was to test the hypothesis that long-term supplementation with Vitamin E improves endothelium-dependent relaxation in hypercholesterolemia patients and/or chronic smoking, two risk factors that have been shown to b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9e5c92d6964c69ed0fb92b210a7bb8
Autor:
Minna Sopo, Maarit Anttila, Hanna Sallinen, Laura Tuppurainen, Anniina Laurema, Svetlana Laidinen, Kirsi Hamalainen, Pasi Tuunanen, Jonna K. Koponen, Veli-Matti Kosma, Seppo Heinonen, Kari Alitalo, Seppo Yla-Herttuala
Publikováno v:
International journal of cancer. 131(10)
We compared effects of antiangiogenic gene therapy with a combination of soluble sVEGFR-1, sVEGFR-2 and sVEGFR-3 to chemotherapy with carboplatin and paclitaxel and to antiangiogenic monoclonal anti-VEGF-antibody bevacizumab in an intraperitoneal ova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fa07133dbf0e5b30e8b61017dd5b122
https://pubmed.ncbi.nlm.nih.gov/22336998
https://pubmed.ncbi.nlm.nih.gov/22336998
Publikováno v:
Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24fc85ad1db32e8f166a3f8a9d0c0ed8
https://doi.org/10.4324/9780203300961_chapter_23
https://doi.org/10.4324/9780203300961_chapter_23
